$TMO

US BROKER MOVES: TMO upgraded at UBS; VMC downgraded at Wells Fargo

UBS upgraded Thermo Fisher Scientific (TMO) to Buy with a $730 price target. Wells Fargo downgraded Vulcan Materials (VMC) to Underweight with a $254 target. Other upgrades and downgrades were announced by various firms.

Original reporting
Published Sep 9, 2026, 12:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 9:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
US BROKER MOVES: TMO upgraded at UBS; VMC downgraded at Wells Fargo — source image
Decision brief

The 30-second read

$TMOBullishLow
01

Why it matters

The article aggregates analyst actions without new company-specific data, offering limited actionable insight.

02

Market read

Provides a snapshot of analyst sentiment shifts but lacks primary new information.

03

What to watch

Potential macro backdrop or earnings season could be driving the flurry of rating changes.

Relevance 4/10Novelty 2/10Timing: today

Background

A daily broker moves roundup listing multiple analyst upgrades, downgrades, and initiations across various sectors.

Company-level read

Ticker impact

$TMOBullishMedium confidence
Context

Thermo Fisher Scientific was upgraded to Buy by UBS with a new price target of $730.

Expected impact

Likely modest price increase on upgrade.

Evidence & confidence

Upgrade to Buy and higher target suggest bullish sentiment, but impact may be limited given many concurrent upgrades.

$VMCBearishMedium confidence
Context

Vulcan Materials was downgraded to Underweight by Wells Fargo with a new price target of $254.

Expected impact

Possible short-term price pressure.

Evidence & confidence

Downgrade to Underweight signals weaker outlook, could trigger sell pressure.

Market effects

Broad coverage of upgrades/downgrades may reflect sector rotation trends.

U.S. equities focus; limited regional effect.

Low global impact.

Counterpoint

The sheer number of analyst actions may dilute individual impact, suggesting a wait-and-see approach.

Key entities

  • Thermo Fisher Scientific

    Upgraded to Buy by UBS.

  • Vulcan Materials

    Downgraded to Underweight by Wells Fargo.

Related articles

$AXPMed

JPMorgan reveals stocks worth buying in October 2026

JPMorgan added five stocks to its Overweight list, highlighting American Express (AXP) as a Value pick, Thermo Fisher (TMO) and Liberty Energy (LBRT) as Growth picks. AXP is down 18-19% YTD but JPMorgan sees steady profits and share buybacks. TMO is up 25% in 3 months, with growth driven by partnerships and AI-powered lab machines. LBRT is up 52% in 12 months, benefiting from AI data center power demands.

$QNTMMed

Quantum BioPharma Taps Thermo Fisher for Lucid-MS Phase 2 Trial in Multiple Sclerosis

Quantum BioPharma (QNTM) has partnered with Thermo Fisher Scientific to begin Phase 2 trials for Lucid-MS, a treatment for progressive multiple sclerosis. The FDA has cleared the trial, which will assess efficacy, safety, and tolerability. Thermo Fisher will provide clinical research services. Success could offer a new treatment option for MS, a condition with limited therapies. Quantum owns 19.84% of Unbuzzd Wellness and receives royalties from it.

$QNTMMedAI 8/10

Quantum BioPharma Advances Multiple Sclerosis Trial with Thermo Fisher Partnership

Quantum BioPharma (QNTM) partnered with Thermo Fisher Scientific to start a Phase 2 trial for Lucid-MS, a treatment for progressive multiple sclerosis. The trial, cleared by the FDA, will assess efficacy, safety, and tolerability. Lucid-MS targets myelin degradation, differing from existing therapies. Quantum owns 19.84% of Unbuzzd Wellness, with royalty agreements in place.

$QNTMMed

Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis

Quantum BioPharma (QNTM) has signed a contract with Thermo Fisher Scientific to implement its Phase 2 clinical trial for Lucid-MS, a treatment for multiple sclerosis. The trial will evaluate the drug's efficacy, safety, and tolerability. Quantum BioPharma received FDA clearance to proceed with the study. The multiple sclerosis market is projected to exceed $38 billion by 2030, according to Grand View Research.